Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Weiterführende Literatur
Adam D et al. (1991) Antibakterielle Therapie bei infektiösen Bronchialerkrankungen. MMW 133: 308
Agence Francaise de Sécurité Sanitaire des Produits de Santé (2001) Troubles de la sécrétion bronchique. www.agmed.sante.gouv.fr/htm/5/smr/pneumo/sebron2.htm. Abgerufen 2003
Agertoft L, Pedersen S (1994) Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Resp. Med. 88: 373
Cumming RG, Mitchell P, Leeder SR (1997) Use of inhaled corticosteroids and the risk of cataracts. New Engl. J. Med. 337: 8
Drazen JM, Israel E, O’Byrne PM (1999) Treatment of asthma with drugs modifying the leukotrien pathway. New Engl. J. Med. 340: 197
Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2001) Am J Respir Crit Care Med 163:1256–1276, http://www.goldcopd.comp/html
International Rhinitis Management Working Group (1994) International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy 49:Suppl 1
Johnson M (1996) Pharmacodynamics and phamacokinetics of inhaled glucocorticoids: J. Allergy Clin. Immunol. 97: 169
Kroegel C, König W, Jäger L (1997) Erweiterte Therapie des Asthma bronchiale — Verwendung von 5-Lipoxygenase-Inhibitoren und Leukotrienantagonisten. Dtsch. Ärztebl. 94: A1802
Leitlinien COPD (2002): http://www.leitlinien.de/themen/infocopd.htm
Mullen ML, Mullen B, Carey M (1993) The association between β-agonist use and death from asthma. JAMA 270: 1842
National Heart, Lung, and Blood Institute (1997) Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma [EPR-2]. National Institutes of Health, pub. no. 97-4051
National Institutes of Health, National Heart, Lung, and Blood Institute (2003) Pocket Guide to COPD Diagnosis, Management, and Prevention, http://www.goldcopd.comp.
National Asthma Education and Prevention Program Expert Panel Report (2002) Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol 110: part 2. http://www2.us.elsevierhealth.com/scripts/om.dll_serve?action=searchDB&searchDBfor=iss&id=jai021105b
Poole PJ, Black PN (2003) Mucolytic agents for chronic bronchitis (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update Software
Schmidt H (1994) Retardtheophyllin ist nicht gleich Retardtheophyllin. Atemwegs-Lungenkr. 20: 223–231
Slater JW, Zechnich AD, Haxby DG (1999) Second-generation antihistamines — a comparative review. Drugs 57: 31
Smolensky MH, D’Alonso GE (1997) Progress in the chronotherapy of nocturnal asthma. In: Redfern P., Lemmer B. (eds.): Physiology and Pharmacology of Biological Rhythms. Handbook of Experimental Pharmacology, Vol. 125, Springer, Berlin, Heidelberg, New York, pp. 205–249
Wettengel R et al. (1998) Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga in der Deutschen Gesellschaft für Pneumologie. Med. Klinik 93: 639–650
WHO Collaborating Centre for Drug Statistics Methodology (2000) ATC Index with DDDs. Oslo
Worth H et al. (2002) Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 56:704–738
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Heidelberg
About this chapter
Cite this chapter
Lemmer, B., Wettengel, R. (2004). Erkrankungen der Atemwege. In: Pharmakotherapie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-35149-3_21
Download citation
DOI: https://doi.org/10.1007/3-540-35149-3_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20414-5
Online ISBN: 978-3-540-35149-8
eBook Packages: Springer Book Archive